ReviewCurrent diabetes reports2008
Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization.
Review in Current diabetes reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 71 citations in OpenAlex.
- Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.Frontiers in immunology · 2023Trial
- Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.Lancet (London, England) · 2011Trial
- Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes.Diabetes · 2011Trial
- Oral Insulin Delay of Stage 3 Type 1 Diabetes Revisited in HLA DR4-DQ8 Participants in the TrialNet Oral Insulin Prevention Trial (TN07).Diabetes care · 2024Article
- Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route.International journal of molecular sciences · 2020Review
- Isogenic Cellular Systems Model the Impact of Genetic Risk Variants in the Pathogenesis of Type 1 Diabetes.Frontiers in endocrinology · 2017Review
- Intestinal Epithelial Cell Regulation of Adaptive Immune Dysfunction in Human Type 1 Diabetes.Frontiers in immunology · 2016Article
- [Type 1 diabetes mellitus. Early detection and prevention].Der Internist · 2015Article
- Antigen-based immunotherapy for autoimmune disease: current status.ImmunoTargets and therapy · 2015Review
- Trials in the prevention of type 1 diabetes: current and future.Canadian journal of diabetes · 2014Review
- Trials in type 1 diabetes: Antigen-specific therapies.Clinical immunology (Orlando, Fla.) · 2013Review
- Cholera toxin subunit B peptide fusion proteins reveal impaired oral tolerance induction in diabetes-prone but not in diabetes-resistant mice.European journal of immunology · 2013Article
- Antigen-based vaccination and prevention of type 1 diabetes.Current diabetes reports · 2013Review
- Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth.Diabetes technology & therapeutics · 2013Article
- Progress in immune-based therapies for type 1 diabetes.Clinical and experimental immunology · 2013Review
- Immune therapy in type 1 diabetes mellitus.Nature reviews. Endocrinology · 2013Review
- Primary and secondary prevention of Type 1 diabetes.Diabetic medicine : a journal of the British Diabetic Association · 2013Review
- Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials.Diabetes · 2013Review
- Clinical immunologic interventions for the treatment of type 1 diabetes.Cold Spring Harbor perspectives in medicine · 2012Review
- New and future immunomodulatory therapy in type 1 diabetes.Trends in molecular medicine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucosal administration of insulin represents an attractive antigen-specific therapeutic approach to preventing type 1 diabetes. It can prevent autoimmune diabetes in animal models, but although it has been shown to be safe, it has not yet been proven effective in human studies. Efficacy may depend on the dose and route at which insulin is administered, the stage in type 1 diabetes pathogenesis at which treatment is initiated, and the study cohort that is treated. We have proposed Pre-POINT (Primary Oral/intranasal INsulin Trial), a dose-finding safety and immune efficacy pilot study for primary mucosal insulin therapy in islet autoantibody-negative children at high genetic risk for type 1 diabetes who naturally first develop autoimmunity to insulin. Pre-POINT aims to identify an optimal insulin dose and route of application (orally or intranasally) that is well tolerated and can induce an immune response to insulin for additional use in a phase II/III primary prevention trial in children at risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.